MARKET

NBY

NBY

Novabay Pharma
AMEX
0.0740
+0.0015
+2.07%
Opening 11:34 04/23 EDT
OPEN
0.0689
PREV CLOSE
0.0725
HIGH
0.0749
LOW
0.0680
VOLUME
892.90K
TURNOVER
0
52 WEEK HIGH
1.520
52 WEEK LOW
0.0650
MARKET CAP
2.67M
P/E (TTM)
-0.0187
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NBY last week (0415-0419)?
Weekly Report · 1d ago
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
NovaBay Pharmaceuticals, Inc. Announces a new and enhanced marketing program that includes text message communications and targeted email programs to drive online sales of Avenova products. The company is developing and commercializing high-quality eyecare and wound care products. NovaBay’s leading product is the Avenova Antimicrobial Lid & Lash Solution.
Barchart · 1d ago
NovaBay Pharmaceuticals receives NYSE notice for compliance
NovaBay Pharmaceuticals, Inc. Receives NYSE notice for compliance. The stock price dropped 2.8% on Friday during after hours of trade. The company must submit a plan by May 18, 2024 to continue listing on the NYSE American. The notice has no immediate effect on the company's stock.
Seeking Alpha · 1d ago
NOVABAY PHARMACEUTICALS RECEIVES A NYSE AMERICAN NOTICE REGARDING STOCKHOLDER EQUITY
Reuters · 3d ago
NOVABAY PHARMACEUTICALS: ON APRIL 18, GOT NOTICE FROM NYSE AMERICAN STATING CO IS BELOW COMPLIANCE WITH NYSE AMERICAN CONTINUED LISTING STANDARDS
Reuters · 3d ago
NovaBay Pharmaceuticals show 13% rise in eyecare and wound care segment - prelim report
Seeking Alpha · 6d ago
NOVABAY PHARMACEUTICALS REPORTS PRELIMINARY EYECARE AND WOUND CARE REVENUE INCREASED 13% FOR THE FIRST QUARTER OF 2024 ON LOWER SALES AND MARKETING EXPENSES
Reuters · 6d ago
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
NovaBay Pharmaceuticals, Inc. Reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million. The increase is attributed primarily to social media marketing programs aimed at consumer sales of the Company’s lead product, Avenova Antimicrobial Lid & Lash Solution.
Barchart · 6d ago
More
About NBY
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.

Webull offers NovaBay Pharmaceuticals Inc stock information, including AMEX: NBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBY stock methods without spending real money on the virtual paper trading platform.